Diabetes Metab J.  2019 Dec;43(6):915-916. 10.4093/dmj.2019.0213.

Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)

• Hwang YC

• KMID: 2466515
• DOI: http://doi.org/10.4093/dmj.2019.0213

Abstract

No abstract available.

MeSH Terms

Diabetes Mellitus, Type 2*
Ezetimibe*
Humans
Rosuvastatin Calcium*
Ezetimibe
Rosuvastatin Calcium

Reference

1. Hwang YC, Jun JE, Jeong IK, Ahn KJ, Chung HY. Comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus. Diabetes Metab J. 2019; 43:582–589.

2. Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013; 10:648–661.

3. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B):2889–2934.